Treatment of Acute Ischemic Stroke.
暂无分享,去创建一个
[1] K. Uchino,et al. Performance of CT Angiography on a Mobile Stroke Treatment Unit: Implications for Triage , 2016, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[2] S. Warach,et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.
[3] J. Edlow,et al. Atypical presentations of acute cerebrovascular syndromes , 2011, The Lancet Neurology.
[4] Gerhard Schroth,et al. What Is a Minor Stroke? , 2010, Stroke.
[5] M. Jayaraman,et al. Stroke vision, aphasia, neglect (VAN) assessment—a novel emergent large vessel occlusion screening tool: pilot study and comparison with current clinical severity indices , 2016, Journal of NeuroInterventional Surgery.
[6] P. Sandercock. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial , 2013, The Lancet Neurology.
[7] H. Diener,et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. , 2015, The New England journal of medicine.
[8] Á. Chamorro,et al. Administration of Uric Acid in the Emergency Treatment of Acute Ischemic Stroke , 2015, Current Neurology and Neuroscience Reports.
[9] D. Schriger,et al. A graphic reanalysis of the NINDS Trial. , 2009, Annals of emergency medicine.
[10] M. Chimowitz. Endovascular treatment for acute ischemic stroke--still unproven. , 2013, The New England journal of medicine.
[11] M. Wintermark,et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[12] H. Naess,et al. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke , 2014, BMC Neurology.
[13] V. Thijs,et al. Thrombolytics in Acute Ischaemic Stroke: Historical Perspective and Future Opportunities , 2013, Cerebrovascular Diseases.
[14] Gregory W Albers,et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.
[15] D. Inzitari,et al. Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[16] G. Donnan,et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. , 2012, The New England journal of medicine.
[17] H. Mattle,et al. Therapy of Basilar Artery Occlusion: A Systematic Analysis Comparing Intra-Arterial and Intravenous Thrombolysis , 2006, Stroke.
[18] Jeffrey L Saver,et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.
[19] J. Berg,et al. Why ischemic stroke patients do not receive thrombolytic treatment: results from a general hospital , 2009, Acta neurologica Scandinavica.
[20] S Hamilton,et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. , 2000, Stroke.
[21] A. Demchuk,et al. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. , 2014, Radiology.
[22] P. Sandercock,et al. Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis , 2015, Stroke.
[23] K. Bulsara,et al. Endovascular Revascularization for Basilar Artery Occlusion , 2014, Interventional Neurology.
[24] L. Munari,et al. RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .
[25] Geoffrey A. Donnan,et al. Stroke Thrombolysis: Save a Minute, Save a Day , 2014, Stroke.
[26] Michael D Hill,et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. , 2013, The New England journal of medicine.
[27] M. Krause,et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. , 2015, The New England journal of medicine.
[28] T. Neumann-Haefelin,et al. Mechanical recanalization in basilar artery occlusion: The ENDOSTROKE study , 2015, Annals of neurology.
[29] Christopher S. Coffey,et al. 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment , 2015 .
[30] J. Grotta,et al. Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical Trial , 2010, Stroke.
[31] M. Lansberg,et al. Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis , 2009, Stroke.
[32] A. Alexandrov,et al. The Role of Sonolysis and Sonothrombolysis in Acute Ischemic Stroke: A Systematic Review and Meta‐analysis of Randomized Controlled Trials and Case‐Control Studies , 2014, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[33] A. Alexandrov,et al. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial , 2009, Annals of neurology.
[34] Joseph P. Broderick,et al. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. , 2005, Annals of emergency medicine.
[35] T. Struffert,et al. Safety and Outcome after Thrombolysis in Stroke Patients with Mild Symptoms , 2008, Cerebrovascular Diseases.
[36] Rong Li,et al. The role of uric acid as a potential neuroprotectant in acute ischemic stroke: a review of literature , 2015, Neurological Sciences.
[37] Terence J Quinn,et al. Assessment scales in stroke: clinimetric and clinical considerations , 2013, Clinical interventions in aging.
[38] S. Warach,et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study , 2009, The Lancet Neurology.
[39] A. Demchuk,et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. , 2015, The New England journal of medicine.
[40] Eric E. Smith,et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. , 2015, The New England journal of medicine.
[41] M. Kaste,et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.
[42] S. Levine,et al. The March of Thrombolytic Therapy for Acute Ischemic Stroke to Clinical Trials: Pre-clinical Thrombolysis and Adjuncts to Thrombolysis Research , 2015 .
[43] M. Conaway,et al. Ninety-Day Outcome Rates of a Prospective Cohort of Consecutive Patients With Mild Ischemic Stroke , 2012, Stroke.
[44] J. Broderick,et al. Design and Validation of a Prehospital Scale to Predict Stroke Severity: Cincinnati Prehospital Stroke Severity Scale , 2015, Stroke.
[45] Thalia Shoshana Field,et al. Tenecteplase–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion , 2015, Stroke.
[46] Tzu-Ching Wu,et al. Hypothermia for acute ischaemic stroke , 2013, The Lancet Neurology.
[47] W. Schleuning,et al. Structural Features Mediating Fibrin Selectivity of Vampire Bat Plasminogen Activators (*) , 1995, The Journal of Biological Chemistry.
[48] M. Chen,et al. Initial hospital management of patients with emergent large vessel occlusion (ELVO): report of the standards and guidelines committee of the Society of NeuroInterventional Surgery , 2015, Journal of NeuroInterventional Surgery.
[49] C. Nolte,et al. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[50] Canadian Association of Emergency Physicians position statement on acute ischemic stroke. , 2015, CJEM.
[51] A. Alexandrov,et al. CLOTBUST-Hands Free: Pilot Safety Study of a Novel Operator-Independent Ultrasound Device in Patients With Acute Ischemic Stroke , 2013, Stroke.
[52] D. Kent,et al. Patient-Centered Decision Support in Acute Ischemic Stroke: Qualitative Study of Patients’ and Providers’ Perspectives , 2015, Circulation. Cardiovascular quality and outcomes.
[53] Eric E. Smith,et al. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry. , 2015, JAMA neurology.
[54] Fernando Vinuela,et al. MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia , 2004, Stroke.
[55] C. Durst,et al. Evolution of endovascular mechanical thrombectomy for acute ischemic stroke. , 2014, World journal of clinical cases.
[56] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[57] Michael D Hill,et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. , 2004, The New England journal of medicine.
[58] H. Naess,et al. A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS) , 2015, BMC Neurology.
[59] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[60] Eric Manheimer,et al. Thrombolysis in acute ischaemic stroke: time for a rethink? , 2015, BMJ : British Medical Journal.
[61] Max Wintermark,et al. A trial of imaging selection and endovascular treatment for ischemic stroke. , 2013, The New England journal of medicine.
[62] E. López‐Cancio,et al. Design and Validation of a Prehospital Stroke Scale to Predict Large Arterial Occlusion: The Rapid Arterial Occlusion Evaluation Scale , 2014, Stroke.
[63] M. Siket,et al. The 10-second stroke: a case report. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[64] Geoff Cohen,et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.
[65] P. Meyers,et al. Embolectomy for stroke with emergent large vessel occlusion (ELVO): report of the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery , 2015, Journal of NeuroInterventional Surgery.
[66] K. Muir,et al. Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke , 2015, Stroke.
[67] A. Algra,et al. Time is Brain(stem) in Basilar Artery Occlusion , 2012, Stroke.
[68] Yufeng Zhou,et al. Comparison of sonothrombolysis efficiencies of different ultrasound systems. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[69] Pooja Khatri,et al. Strokes With Minor Symptoms: An Exploratory Analysis of the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trials , 2010, Stroke.
[70] Lisa H. Merck,et al. The Emergency Medicine Debate on tPA for Stroke: What Is Best for Our Patients? Efficacy in the First Three Hours. , 2015, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[71] Elad I Levy,et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial , 2012, The Lancet.
[72] J. Kirmani,et al. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator? , 2010, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[73] A. Majid,et al. Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review , 2013, Stroke research and treatment.
[74] L. Schwamm. Acute Stroke: Shifting From Informed Consent to Informed Refusal of Intravenous Tissue-Type Plasminogen Activator. , 2015, Circulation. Cardiovascular quality and outcomes.
[75] Joel Stein,et al. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. , 2014, Circulation.
[76] M. Hommel,et al. Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.
[77] D. Tanné,et al. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study , 2009, The Lancet Neurology.
[78] A. Demchuk,et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. , 2001 .
[79] G. Zaharchuk,et al. Angiographic Outcome of Endovascular Stroke Therapy Correlated with MR Findings, Infarct Growth, and Clinical Outcome in the DEFUSE 2 Trial , 2014, International journal of stroke : official journal of the International Stroke Society.
[80] M. Luby,et al. A Pragmatic Approach Using Magnetic Resonance Imaging to Treat Ischemic Strokes of Unknown Onset Time in a Thrombolytic Trial , 2012, Stroke.
[81] G. Micieli,et al. Safety and efficacy of alteplase in the treatment of acute ischemic stroke , 2009, Vascular health and risk management.
[82] J. Grotta,et al. Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial , 2015, The Lancet Neurology.
[83] J. Saver. Time Is Brain—Quantified , 2006, Stroke.
[84] J. F. Johnson,et al. ANTICOAGULANTS PLUS STREPTOKINASE THERAPY IN PROGRESSIVE STROKE. , 1964, JAMA.
[85] Keith Muir,et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.
[86] S. Ricci,et al. Sonothrombolysis for acute ischaemic stroke. , 2012, The Cochrane database of systematic reviews.
[87] J. Wardlaw,et al. Thrombolysis for acute ischaemic stroke. , 2014, The Cochrane database of systematic reviews.
[88] V. Bonito,et al. Thrombolysis for acute ischemic stroke: the problem of consent , 2001, Neurological Sciences.
[89] R. Conwit,et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. , 2015, The New England journal of medicine.
[90] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[91] Hester F. Lingsma,et al. A randomized trial of intraarterial treatment for acute ischemic stroke. , 2015, The New England journal of medicine.
[92] M. Kaste,et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.
[93] J. Wardlaw,et al. Cochrane reviewers’ response to Alper and colleagues’ analysis of thrombolysis in acute ischaemic stroke , 2015, BMJ : British Medical Journal.
[94] S. Kiechl,et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis , 2013, Neurology.
[95] A. Alexandrov,et al. Safety and Efficacy of Ultrasound-Enhanced Thrombolysis: A Comprehensive Review and Meta-Analysis of Randomized and Nonrandomized Studies , 2010, Stroke.
[96] Eric E. Smith,et al. Endovascular Clot Retrieval Therapy: Implications for the Organization of Stroke Systems of Care in North America , 2015, Stroke.
[97] D. Combs,et al. Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction , 2002, Clinical pharmacokinetics.
[98] R. Medcalf,et al. t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. , 2012, Blood.
[99] A. Alexandrov,et al. Reperfusion Therapies of Acute Ischemic Stroke: Potentials and Failures , 2014, Front. Neurol..
[100] Penumbra Pivotal Stroke Trial Investigators. The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease , 2009, Stroke.
[101] Gregory W Albers,et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial , 2012, The Lancet.
[102] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[103] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[104] Liping Liu,et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. , 2013, The New England journal of medicine.
[105] J. Grimshaw,et al. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC) :a cluster randomised controlled trial , 2015 .
[106] M. Fisher,et al. Future directions of acute ischaemic stroke therapy , 2015, The Lancet Neurology.
[107] R. Cooper,et al. How is more negative evidence being used to support claims of benefit: The curious case of the third international stroke trial (IST‐3) , 2012, Emergency medicine Australasia : EMA.
[108] T. Louis,et al. Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial , 2004, Stroke.
[109] P. Sandercock,et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .
[110] R. Marshall. Progress in Intravenous Thrombolytic Therapy for Acute Stroke. , 2015, JAMA neurology.
[111] J. Purrucker,et al. Comparison of stroke recognition and stroke severity scores for stroke detection in a single cohort , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[112] W. Hacke,et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke , 1992, Annals of neurology.
[113] Eric E. Smith,et al. Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke , 2005, Stroke.
[114] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.
[115] S. Johnston,et al. Why are eligible thrombolysis candidates left untreated? , 2006, American journal of preventive medicine.
[116] Adrian F Hernandez,et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. , 2013, JAMA.
[117] J. F. Johnson,et al. Therapeutic thrombolysis in cerebral thromboembolism , 1963, Neurology.
[118] G. Schlaug,et al. The Stroke Patient Who Woke Up: Clinical and Radiological Features, Including Diffusion and Perfusion MRI , 2002, Stroke.
[119] Á. Chamorro,et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial , 2014, The Lancet Neurology.
[120] Bruce C V Campbell,et al. Role of imaging in current acute ischemic stroke workflow for endovascular therapy. , 2015, Stroke.
[121] Joseph P Broderick,et al. Basilar Occlusion Syndromes , 2015, The Neurohospitalist.
[122] Steven Warach,et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.
[123] Thomas Brott,et al. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. , 2005, Annals of emergency medicine.
[124] A. Alexandrov,et al. Safety of Intravenous Thrombolysis in Stroke Mimics: Prospective 5-Year Study and Comprehensive Meta-Analysis , 2015, Stroke.
[125] D. Liebeskind,et al. Assessment and Improvement of Figures to Visually Convey Benefit and Risk of Stroke Thrombolysis , 2010, Stroke.
[126] Jeffrey L. Saver,et al. Extending Reperfusion Therapy for Acute Ischemic Stroke: Emerging Pharmacological, Mechanical, and Imaging Strategies , 2005, Stroke.
[127] X. Ji,et al. Therapeutic hypothermia for stroke: Where to go? , 2015, Experimental Neurology.
[128] S. Levine,et al. Prehospital stroke scales in urban environments , 2014, Neurology.
[129] M. Ribeiro,et al. Wake-up Stroke and Stroke within the Therapeutic Window for Thrombolysis Have Similar Clinical Severity, Imaging Characteristics, and Outcome. , 2016, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[130] Joseph P Broderick,et al. Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.
[131] R. Higashida,et al. Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .
[132] Nita A. Farahany,et al. Testing the presumption of consent to emergency treatment for acute ischemic stroke. , 2014, JAMA.
[133] Adnan I. Qureshi,et al. Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .
[134] D. Mozaffarian,et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. , 2014, Circulation.
[135] J. Mocco,et al. State of acute endovascular therapy: report from the 12th thrombolysis, thrombectomy, and acute stroke therapy conference. , 2015, Stroke.
[136] L. Schwamm,et al. Endovascular Approaches to Acute Stroke, Part 1: Drugs, Devices, and Data , 2009, American Journal of Neuroradiology.
[137] E. Jauch,et al. Intravenous Thrombolytic Therapy for Acute Ischemic Stroke: Results of Large, Randomized Clinical Trials , 2015 .
[138] I. Ford,et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study , 2015, The Lancet Neurology.
[139] Michela Ponzio,et al. Endovascular treatment for acute ischemic stroke. , 2013, The New England journal of medicine.
[140] Christopher S Coffey,et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.